Navigation Links
Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma

MONTREAL, Jan. 26 /PRNewswire/ - Aegera Therapeutics Inc. announced today the successful completion of a dose-ranging Phase 1 study and the initiation of a randomized Phase 2 study of AEG35156 in combination with sorafenib for the treatment of patients with advanced hepatocellular carcinoma (primary liver cancer).

This new study, entitled "A Phase 2, Open-Label Study of The X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination with Sorafenib in Patients With Advanced Hepatocellular Carcinoma", is being conducted in Hong Kong. The study is projected to recruit approximately 50 patients with two thirds receiving the combination of AEG35156 and sorafenib and one third receiving sorafenib alone.

"We are pleased with the conduct and results of the Phase 1 portion of this trial. AEG35156 appears to be well tolerated when given in combination with sorafenib. We are now focused on completing recruitment to the randomized Phase 2 portion of the clinical trial to determine if the AEG35156/sorafenib combination can bring an additional therapeutic benefit to this under-served oncology population," stated Dr. Jacques Jolivet, Senior Vice-President of Clinical Development of Aegera.

About AEG35156

AEG35156 is a 2nd generation antisense oligonucleotide which targets XIAP; it is designed to lower the apoptotic threshold of cancer cells, enhancing their sensitivity to intrinsic death and chemotherapy, without harming healthy cells. Other currently enrolling studies include a randomized Phase 2 study for the treatment of acute myeloid leukemia and a Phase 1/2 monotherapy study in CLL/indolent B-cell lymphomas, which is fully funded by The Leukemia and Lymphoma Society of North America.

About Aegera Therapeutics Inc.

Aegera Therapeutics is a clinical stage biotechnology company focused on developing novel targeted therapies that address major unmet medical needs. In addition to AEG35156, Aegera is completing a Phase 2A study of AEG33773 in diabetic neuropathic pain and is working with its partner Human Genome Sciences (HGSI) to progress HGS1029 through early stage clinical development. Additional information on these programs can be found on Aegera's website at


Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
2. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
3. Aegera Therapeutics welcomes two experienced executives to its board of directors
4. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
5. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
6. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
7. Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain
8. Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
9. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
10. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
11. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
Post Your Comments:
(Date:11/24/2015)... LUMPUR, Malaysia , Nov. 24, 2015 /PRNewswire/ ... global contract research organisation (CRO) market. The trend ... result in lower margins but higher volume share ... increased capacity and scale, however, margins in the ... Research Organisation (CRO) Market ( ), ...
(Date:11/24/2015)... 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended September 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... said Andrew Rae , President & CEO ... not only value enriching for this clinical program, ...
(Date:11/24/2015)... 2015  Clintrax Global, Inc., a worldwide provider of clinical research ... announced that the company has set a new quarterly earnings record ... quarter growth posted for Q3 of 2014 to Q3 of 2015. ... Mexico , with the establishment of an Asia-Pacific ... United Kingdom and Mexico ...
(Date:11/24/2015)... Massachusetts , November 24, 2015 SHPG ... will participate in the Piper Jaffray 27 th Annual Healthcare ... Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ... , Chief Financial Officer, will participate in the Piper Jaffray 27 ... , NY on Tuesday, December 1, 2015, at 8:30 a.m. ...
Breaking Biology Technology:
(Date:11/17/2015)... Mass. , Nov. 17, 2015 Pressure ... leader in the development and sale of broadly enabling, ... worldwide life sciences industry, today announced it has received ... its $5 million Private Placement (the "Offering"), increasing the ... $4,025,000.  One or more additional closings are expected in ...
(Date:11/11/2015)... 11, 2015   MedNet Solutions , an innovative SaaS-based ... research, is pleased to announce that it will be a ... event, to be held November 17-19 in ... live demonstrations of iMedNet , MedNet,s easy-to-use, ... iMedNet has been able to deliver time and cost ...
(Date:11/4/2015)... , November 4, 2015 ... new market report published by Transparency Market Research "Home Security ... Trends and Forecast 2015 - 2022", the global home security ... 30.3 bn by 2022. The market is estimated to ... period from 2015 to 2022. Rising security needs among ...
Breaking Biology News(10 mins):